TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 2 9% etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 27,100 shares, an increase of 22.1% from the May 15th total of 22,200 shares. Currently, 4.4% of the shares of the stock are sold short. Based on […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 27,100 shares, a growth of 22.1% from the May 15th total of 22,200 shares. Based on an average daily trading volume, of 162,200 shares, the days-to-cover ratio […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley purchased 19,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was acquired at an average price of $2.76 per share, with a total value of $52,440.00. Following the completion of the purchase, the chief executive officer […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) CEO Robert Michael Dudley bought 19,000 shares of the stock in a transaction on Friday, June 9th. The shares were acquired at an average cost of $2.76 per share, for a total transaction of $52,440.00. Following the acquisition, the chief executive officer now directly owns 912,114 shares in […]